Logo of The Hydration Pharmaceuticals Company (ASX:HPC)Latest The Hydration Pharmaceuticals Company (ASX:HPC) News

Page 1
Page 1 of 2

HPC cuts Q3 US operating loss 85% as revenue falls 21.9%

Hydration Pharmaceuticals sharply reduced Hydralyte LLC’s US operating loss in the September quarter after cutting costs and refocusing marketing. But weaker September trading, stock-outs, limited cash and an ununderwritten entitlement offer leave the turnaround unfinished.
Victor Sage
11 Nov 2026

Hydralyte records first monthly profit as quarterly loss falls 85%

Hydralyte LLC recorded its first monthly operating profit in August, while a major cost reset cut its quarterly operating loss to US$66,900. But revenue fell 21.9%, cash narrowed to US$173,400 and the company is seeking up to A$1.4 million through a rights issue.
Victor Sage
30 Oct 2026

Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Healthcare shares ended a difficult week with funding worries weighing on smaller companies, even as several groups reported stronger sales or clinical progress. Starpharma, Hydration Pharmaceuticals and Saluda were among the largest fallers, while Recce, Zoono and Genetic Signatures posted gains.
Logan Eniac
24 Oct 2026

HPC seeks A$1.43 million to fund working capital after US business turns profitable

Hydration Pharmaceuticals is asking eligible shareholders for up to A$1.43 million in fresh capital as it funds the next phase of its turnaround. The non-renounceable offer comes with free options, but is neither underwritten nor subject to a minimum subscription.
Ada Torres
23 Oct 2026

Hydralyte cuts EBITDA loss 75% as US business turns monthly profitable

The Hydration Pharmaceuticals Company (ASX:HPC) has sharply reduced its operating losses, with Hydralyte LLC recording its first monthly EBITDA profit in August. The group remains loss-making overall, but improved margins and a lower cost base are beginning to show in the numbers.
Victor Sage
29 Sept 2026

Market Wrap - Week 25 (15 June -> 19 June) 2026

Small caps drove the week, with battery, resources and education names posting the biggest gains. Deal news, funding rounds and fresh drilling plans kept traders busy, while a few discounted raisings hit hard.
Logan Eniac
20 June 2026

Hydralyte USA Raises A$392k, Revamps Board and Cuts Costs to Boost US Growth

Hydralyte USA secures A$392,000 through a share placement, appoints two new non-executive directors, and implements significant cost reductions following CEO resignation as it targets cash-flow break-even and strategic expansion.
Victor Sage
15 June 2026

Healthcare Wrap - Week 19 (4 May -> 8 May) 2026

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.
Logan Eniac
9 May 2026

HPC Returns to ASX Trading After Reporting $2.86M Loss

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.
Ada Torres
4 May 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Hydration Pharmaceuticals Reports $2.86M Loss, Eyes Strategic Moves Amid Trading Halt

The Hydration Pharmaceuticals Company Limited (ASX: HPC) temporarily halted trading to relodge its FY25 Annual Report, revealing a $2.86 million loss driven by US market rationalisation and ongoing cost-cutting.
Ada Torres
1 May 2026

Healthcare Wrap - Week 8 (16 Feb -> 20 Feb) 2026

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.
Logan Eniac
21 Feb 2026